in the hot seat

Judges named for 2022 Houston Innovation Awards

Here's who's making the call for this year's Houston Innovation Awards. Photos courtesy

Nominations are closed, applications are out, and the city of Houston is waiting to see who are the finalists for the 2022 Houston Innovation Awards. But first — who are tasked with the job of deciding the honorees for the Houston Innovation Awards Gala on November 9?

Click here to secure your tickets to the event.

A cohort of eight of the best innovation leaders in the Bayou City — representing all corners of tech and innovation, from energy and hard tech to software and startup acceleration. Introducing: The 2022 Houston Innovation Awards judges:

Carolyn Rodz, founder and CEO of Hello Alice

Carolyn Rodz, founder and CEO of Hello Alice

Photo courtesy of Hello Alice

Carolyn Rodz is a leader in Houston innovation — both as a startup founder and as a resources for startups and small businesses across the country. As CEO, she leads Hello Alice, a company Rodz founded with Elizabeth Gore, on its mission to provide support and guidance to small business owners.

Rodz is no stranger to InnovationMap's awards program. Last year, Hello Alice was a finalist in three categories and took home the win for BIPOC-owned business.

Wogbe Ofori, founder of Wrx Companies

Photo courtesy

​Wogbe Ofori is a champion of Houston innovation, startup mentor, investor, and more. He's particularly passionate about hard tech and serves as an adviser to Houston-based Nauticus Robotics and CaringBand. He also participates as a mentor across several organizations, including MassChallenge, Capital Factory, Founder Institute, and the University of Houston.

Scott Gale, executive director of Halliburton Labs

Photo courtesy

After several years in strategy at Halliburton, Scott Gale switched gears to lead Halliburton Labs, which launched in 2020. The startup incubation lab focuses on supporting early-stage companies within climatetech and the future of energy.

Ashley Danna, senior manager of regional economic development of Greater Houston Partnership

Photo courtesy

It's Ashley Danna's job at GHP to have a pulse on companies in Houston — including tech and life science businesses. Her role is focused on marketing the Houston region as a business magnet to expanding and relocating domestic businesses to foster job creation and economic growth while collaborating and strengthening relationships with external stakeholders.

Kelly McCormick, professor at the University of Houston

Photo courtesy

Kelly McCormick has spent the better part of a decade molding young, entrepreneurial minds at the University of Houston, both as a professor and as leading UH's student startup accelerator, Red Labs.

Paul Cherukuri, vice president of innovation at Rice University

Photo courtesy of Rice

Paul Cherukuri, the executive director of the Institute of Biosciences and Bioengineering, was named the inaugural vice president for innovation at Rice University in August. In his role, Cherukuri leads Rice’s technology and commercialization infrastructure to translate breakthrough discoveries into inventions for the benefit of society.

Lawson Gow, CEO of Houston Exponential

Photo courtesy of The Cannon

Lawson Gow wears many hats within the Houston innovation ecosystem. He founded The Cannon, a Houston-wide coworking company, and now oversees Houston Exponential. He also is the founder and CEO of sportstech-focused Pokatok and chief strategy officer of SportsMap SPAC.

Natalie Harms, editor of InnovationMap

Photo courtesy

Natalie Harms has been at the helm of InnovationMap — Houston's voice for Innovation — since its inception in October 2018. She oversees all editorial operations of the site and hosts its weekly podcast, the Houston Innovators Podcast.

Trending News

Building Houston

 
 

You can now hop online and invest in this promising cell therapy startup. Photo via Getty Images

A clinical-stage company headquartered in Houston has opened an online funding campaign.

FibroBiologics, which is developing fibroblast cell-based therapeutics for chronic diseases, launched a campaign with equity crowdfunding platform StartEngine. The platform lets anyone — regardless of their net worth or income level — to invest in securities issued by startups.

The funding, according to a press release, will be used to support ongoing operations of Fibrobiologics and advance its clinical programs in multiple sclerosis, degenerative disc disease, wound care, extension of life, and cancer.

"We're excited to partner with StartEngine on this campaign. StartEngine has over 600,000 investors as part of their community and has raised over half a billion dollars for its clients," says FibroBiologics' Founder and CEO Pete O'Heeron, in the release.

"This is an exciting time at FibroBiologics as we continue progressing our clinical pipeline and developing innovative therapies to treat chronic diseases," he continues. "This new funding will fuel our growth in the lab and bring us one step closer to commercialization."

The campaign, launched this week, already has over 100 investors, at the time of publication, and has raised nearly $2 million, according to the page. The minimum investment is set at around $500, and the company's indicated valuation is $252.57 million.

In 2021, FibroBiologics announced its intention of going public. Last year, O'Heeron told InnovationMap on the Houston Innovators Podcast of the company's growth plans as well as the specifics of the technology.

Only two types of cells — stem cells and fibroblasts — can be used in cell therapy for a regenerative treatment, which is when specialists take healthy cells from a patient and inject them into a part of the body that needs it the most. As O'Heeron explains in the podcast, fibroblasts can do it more effectively and cheaper than stem cells.

"(Fibroblasts) can essentially do everything a stem cell can do, only they can do it better," says O'Heeron. "We've done tests in the lab and we've seen them outperform stem cells by a low of 50 percent to a high of about 220 percent on different disease paths."


Trending News